Monoclonal Antibody Collaboration and Licensing Analysis Report 2024 with Directory of 639 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapeutic Target
November 26, 2024 06:29 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and...
$55.7 Billion Biopharmaceutical Fermentation Systems Market Opportunities and Strategies to 2033: Development of New Bioreactors to Enhance Single-Use Upstream Operations, New Technology Developments
November 22, 2024 05:54 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Fermentation Systems Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. The...
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
November 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
CC Chemokine Receptor Type 5 Market Research Report 2024
November 07, 2024 09:35 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC chemokine receptor type 5 market...
SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer
November 07, 2024 07:00 ET
|
SynOx Therapeutics Limited
Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients...
SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial
October 30, 2024 07:00 ET
|
SynOx Therapeutics Limited
Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1...
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:55 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic...
Biopharmaceuticals Manufacturing Consumables Testing Business Research Report 2024-2030
October 18, 2024 04:30 ET
|
Research and Markets
Dublin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Manufacturing Consumables Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments
October 14, 2024 10:58 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ...
Tularemia Pipeline Landscape Report 2024: Current Treatment Paradigm and Future Prospects, Strategic Collaborations and Clinical Progress
September 24, 2024 10:13 ET
|
Research and Markets
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Tularemia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The Tularemia pipeline landscape is witnessing a...